Activating B-Raf mutations that deregulate the MAPK pathway commonly occur in cancer. Whether additional proteins modulate the enzymatic activity of oncogenic B-Raf is unknown. Here we show that the proto-oncogene C-Raf paradoxically inhibits B-Raf V600E kinase activity through the formation of B-Raf V600E -C-Raf complexes. Although all Raf family members associate with oncogenic B-Raf, this inhibitory effect is specific to C-Raf. Indeed, a B-Raf V600E isoform with impaired ability to interact with C-Raf exhibits elevated oncogenic potential. Human melanoma cells expressing B-Raf V600E display a reduced C-Raf:B-Raf ratio, and further suppression of C-Raf increases MAPK activation and proliferation. Conversely, ectopic C-Raf expression lowers ERK phosphorylation and proliferation. Moreover, both oncogenic Ras and Sorafenib stabilize B-Raf V600E -C-Raf complexes, thereby impairing MAPK activation. This inhibitory function of C-Raf on B-Raf V600E -mediated MAPK activation may explain the lack of co-occurrence of B-Raf V600E and oncogenic Ras mutations, and influence the successful clinical development of small molecule inhibitors for B-Raf V600E -driven cancers.
INTRODUCTION
The mitogen-activated protein kinase (MAPK) pathway relays signals from the plasma membrane to the nucleus, thereby regulating the cell's response to extracellular stimuli. This response encompasses diverse cell biological processes such as proliferation, growth, differentiation, and apoptosis (Robinson and Cobb, 1997; Wellbrock et al., 2004a) . To ensure proper control of these processes, the MAPK pathway is tightly regulated. Upon ligand binding to receptor tyrosine kinases, the small G protein Ras becomes activated and signals to the MAPK pathway and to several other effector pathways. Active Ras recruits Raf serine/threonine kinases (A-Raf, B-Raf, and C-Raf) to the plasma membrane, where they become activated by regulatory phosphorylation and dephosphorylation events, conformational changes, and binding to other proteins (Wellbrock et al., 2004a) . Active Raf phosphorylates MEK (for MAPK and extracellular signal-regulated kinase [ERK] kinase), which subsequently phosphorylates ERK. ERK translocates to the nucleus, where it initiates diverse gene expression programs by activating transcription factor families such as ETS and AP-1.
Since the MAPK pathway controls cellular processes that are often perturbed in human malignancy, it is not surprising that deregulation of the pathway is commonly observed in cancer. Indeed, activating Ras mutations are found in approximately 30% of human neoplasms (Bos, 1989) . More recently, B-Raf mutations were reported in 7% of human cancers (Brose et al., 2002; Davies et al., 2002; Pollock and Meltzer, 2002) , and two classes of B-Raf mutations have been identified. The majority of B-Raf mutations hyperactivate its kinase function, and B-Raf V600E represents the most prominent example of this class.
In contrast, three tumor-associated mutations (G466V, G466E, G596R) weaken the catalytic activity of B-Raf. These mutants have been proposed to stimulate C-Raf activity through physical interaction, thereby hyperactivating the MAPK pathway (Garnett et al., 2005; Wan et al., 2004) . A link between mutations activating the MAPK pathway and cancer development was provided by genetically engineered mouse models. Mice expressing endogenous oncogenic Kras or B-Raf develop preneoplasms in several tissues (Karreth and Tuveson, 2009) . Cells isolated from these mice display activation of the MAPK pathway and are partially transformed (Mercer et al., 2005; Tuveson et al., 2004) . Interestingly, despite possessing oncogenic potential in vivo (Kerkhoff et al., 2000) and in vitro (Heidecker et al., 1990; Stanton et al., 1989) , activating mutations in C-Raf that lead to abnormal MAPK signaling are extremely rare and have only been observed in two cases of AML thus far (Zebisch et al., 2006) . Raf proteins associate in response to Ras stimulation, and complexes containing either two copies of the same Raf protein or one copy of two different Raf proteins have been observed (Farrar et al., 1996; Luo et al., 1996; Weber et al., 2001 ). Indeed, wild-type B-Raf can signal to MEK/ERK by binding and activating C-Raf (Garnett et al., 2005) , and B-Raf-C-Raf complexes possess higher kinase activity toward MEK than complexes containing only B-Raf or C-Raf (Rushworth et al., 2006) . Additionally, impaired-activity B-Raf mutants that require C-Raf to relay signals to MEK and ERK constitutively bind and activate C-Raf (Wan et al., 2004) , leading to MAPK hyperactivation (Garnett et al., 2005; Wan et al., 2004) . Together, these findings imply that association of Raf proteins plays an important role in regulating MAPK signal intensity and may participate in controlling the biological output of MAPK activation.
A crucial role for C-Raf in the activation of the MAPK pathway by B-Raf mutants with impaired catalytic function has been established. However, whether C-Raf is able to modulate B-Raf V600E -mediated signaling is unknown. Here we report that C-Raf surprisingly inhibits B-Raf V600E -induced MAPK activation and transformation through formation of a B-Raf V600E -C-Raf complex with reduced kinase activity. Furthermore, oncogenic Ras stimulates activation of C-Raf and association with B-Raf V600E to diminish MAPK signaling and proliferation, providing a rationale for the lack of co-occurrence of oncogenic Ras and B-Raf V600E mutations in cancer. Finally, incubation of B-Raf V600E -expressing cells with the Raf kinase inhibitor Sorafenib results in stabilization of the C-Raf-B-Raf complex, providing additional insight into the mechanism of action of this and potentially other Raf kinase inhibitors.
RESULTS

Effects of C-Raf on MAPK Pathway Activation by Oncogenic B-Raf Mutants
To study modulation of oncogenic B-Raf signaling by C-Raf, mutant B-Raf and C-Raf were transiently expressed in HEK293T cells, and ERK activation was examined. Concomitant expression of B-Raf G466V and C-Raf promoted MAPK activation ( Figure 1A ). In contrast, coexpression of B-Raf V600E and C-Raf resulted in a marked decrease of phosphorylated ERK (pERK) levels compared to expression of B-Raf V600E alone ( Figure 1A ), suggesting a suppressive effect of C-Raf on B-Raf V600E . We next determined whether C-Raf activity is required for suppression by coexpressing C-Raf mutants with severely reduced kinase activity with B-Raf V600E . While C-Raf K375M failed to suppress B-Raf V600E signaling, B-Raf
V600E
-mediated ERK activation was reduced by C-Raf S338A ( Figure 1B) . Interestingly,
, but not C-Raf
K375M
, cooperated with B-Raf G466V to promote MAPK pathway activation ( Figure 1B and Garnett et al., 2005) , suggesting that Ras-induced phosphorylation of C-Raf at Ser338 is not required for suppression of B-Raf
V600E
and cooperation with B-Raf
G466V
. The extent of interaction between C-Raf K375M and B-Raf has been reported to be reduced, while binding of C-Raf S338A to B-Raf is not affected by the mutation (Rushworth et al., 2006) . Similarly, binding of C-Raf
K375M
, but not C-Raf S338A , to B-Raf V600E was markedly impaired ( Figure 1C ), suggesting that binding to C-Raf is required, while C-Raf kinase activity is dispensable for suppression of B-Raf V600E . Since C-Raf K375M did not bind and suppress B-Raf V600E , we reasoned that the direct association of C-Raf with -CRaf complexes was significantly reduced ( Figure 1D ). Thus, C-Raf has an unexpected inhibitory function on MAPK pathway activation by associating with B-Raf V600E , thereby reducing the kinase activity of the complex.
Suppression of B-Raf
V600E Signaling Is Specific to C-Raf and Not Due to Activation of Negative Feedback Loops We next determined whether wild-type B-Raf and A-Raf possess suppressive activities similar to C-Raf. Interestingly, coexpression of wild-type B-Raf did not suppress B-Raf V600E ( Figure 2A ). Conversely, wild-type B-Raf enhanced MAPK activation by B-Raf G466V to similar levels as C-Raf ( Figure 2A) . B-Raf -G466V  +  ---+  -----+  ---+  ---+  ---+ . Intriguingly, A-Raf failed to cooperate with B-Raf G466V to promote MAPK pathway activation ( Figure 2B ).
The binding efficiency of A-Raf to B-Raf V600E was similar to that of C-Raf ( Figure 2C) ; hence, the lack of a suppressive function of A-Raf was not due to reduced complex formation of A-Raf with B-Raf
V600E
. Thus, suppression of B-Raf V600E signaling is specific to C-Raf, while both C-and B-Raf can cooperate with B-Raf G466V . To exclude the possibility that coexpression of oncogenic B-Raf and C-Raf activates negative feedback loops, thus leading to reduced pERK expression, we analyzed phosphorylation of MEK to more accurately determine the activity of B-Raf mutants. Similar to the results regarding pERK, coexpression of C-Raf and B-Raf V600E diminished MEK activation, while concomitant expression of C-Raf and B-Raf G466V further induced phosphorylation of MEK when compared to expression of the respective B-Raf mutants alone ( Figure 2D ). Finally, expression levels of dual specificity phosphatases (DUSP4 and DUSP6) as well as Sprouty 2, known negative modulators of the MAPK pathway, were unchanged upon expression of B-Raf V600E or B-Raf G466V alone or in combination with C-Raf ( Figure 2E ). Therefore, modulation of oncogenic B-Raf-induced MAPK pathway activation by C-Raf is not mediated by activation of negative feedback loops.
Interaction of C-Raf and Oncogenic B-Raf V600E Impairs
Cellular Transformation
We identified a murine splice form of B-Raf (termed D3-B-Raf) that lacked 33 amino acids within exon 3. The sequence of D3-B-Raf has been noted in GenBank for mouse (e.g., NM_139294) and rat (e.g., XM_231692). D3-B-Raf interacts with C-Raf less efficiently (see Figures S1-S3 available online) and was utilized to study the effect of B-Raf-C-Raf interaction on cellular transformation by oncogenic B-Raf. Decreased basal and Hras G12V -induced binding of D3-B-Raf G466V to C-Raf was accompanied by reduced activation of the MAPK pathway (Figures S4A and S4B) . Moreover, stimulation of proliferation and anchorage-independent growth in soft agar by D3-B-Raf
G466V
was less pronounced when compared to B-Raf G466V ( Figures  S4C and S4D ). These findings further support the notion that complex formation of C-Raf and B-Raf G466V promotes activation of the MAPK pathway. We next determined whether reduced interaction with C-Raf increased the oncogenic potential of B-Raf V600E . First, expression in HEK293T cells showed that, in contrast to impairedactivity mutants (Garnett et al., 2005) , B-Raf V600E or D3-BRaf V600E only very inefficiently interact with endogenous C-Raf ( Figure 3A ). Coexpression with Hras G12V induced association of full-length B-Raf V600E and, to a lesser extent, of D3-B-Raf
V600E
with C-Raf ( Figure 3A ). Strikingly, Hras G12V -mediated complex formation of C-Raf with B-Raf V600E diminished B-Raf V600E -driven phosphorylation of ERK, and reduction of pERK levels was less pronounced in cells expressing D3-B-Raf V600E compared to full-length B-Raf V600E (19% versus 26% reduction, Figure 3A ).
Ectopic expression of B-Raf V600E has been shown to transform the immortalized melanocyte cell line melan-a (Wellbrock et al., 2004b) , confirming B-Raf's oncogenic potential in melanoma (Davies et al., 2002) . Therefore, full-length B-Raf V600E and D3-B-Raf V600E were stably expressed in melan-a cells to assess the role of B-Raf V600E -C-Raf complex formation on cellular transformation. D3-B-Raf V600E expression stimulated ERK activation and TPA-independent proliferation more efficiently than To investigate whether the antagonistic function of C-Raf toward B-Raf V600E was apparent in melanoma, the relative amounts of C-Raf and B-Raf were assessed in a panel of human melanoma cell lines and compared to a human melanocyte cell line (normal human epidermal melanocytes, NHEMs). All investigated melanoma cell lines harboring B-Raf V600E displayed a reduced C-Raf:B-Raf ratio when compared to NHEM ( Figure 4A ). In contrast, Nras mutant cells exhibited similar C-Raf levels but lower B-Raf levels than NHEM, resulting in an increased C-Raf:B-Raf ratio ( Figure 4A ). These results indicate that the reduction of C-Raf levels relative to B-Raf is specific to melanoma cells harboring B-Raf V600E and does not occur in cell lines that activate the MAPK pathway through other means. To assess whether relative Raf levels in NHEM are representative of melanocytes, expression of B-Raf and C-Raf was compared to another human melanocytes cell line, Fom99. C-Raf expression in Fom99 melanocytes was increased compared to NHEM, resulting in a higher C-Raf:B-Raf ratio in these cells ( Figure S5A) . Thus, the reduction of the C-Raf:B-Raf ratios in B-Raf V600E mutant melanoma cell lines compared to melanocytes is a general finding. For the observed reduction of the C-Raf:B-Raf ratio in B-Raf V600E melanoma cells to be biologically relevant, C-Raf and B-Raf molecules should be present at comparable levels in such cells. To address this, the quantity of B-Raf and C-Raf molecules per cell was determined in several melanoma cell lines using recombinant B-Raf and C-Raf as reference standards ( Figure S5B ). Importantly, the amounts of B-Raf and C-Raf molecules expressed per cell were similar in all investigated cell lines ( Figure S5C ). Finally, A-Raf expression was not significantly changed and did not correlate with B-Raf mutation status ( Figure S5D ), which is consistent with the lack of suppressive activity toward B-Raf To analyze whether further reducing the expression levels of C-Raf affects MAPK activation and cell proliferation in human B-Raf V600E and Nras mutant melanoma cell lines, C-Raf was depleted using RNAi. C-Raf protein levels were decreased significantly following knockdown, while B-Raf levels were unchanged ( Figure 4B ). Interestingly, abrogation of C-Raf expression in the B-Raf V600E -expressing cell lines WM793, WM164, and WM983A promoted increased ERK phosphorylation ( Figure 4B ). In contrast, decreased pERK levels were observed upon C-Raf depletion in the N-Ras mutant cell line SKMel2 ( Figure 4B ), consistent with published data (Dumaz et al., 2006) . Next, the effect of enhanced MAPK signaling on proliferation of melanoma cells was determined by labeling shRNA-treated cells with BrdU. C-Raf depletion was accompanied by a moderate increase in proliferation of WM793, WM164, and WM983A cells, whereas Nras mutant cells exhibited reduced proliferation upon C-Raf depletion ( Figure 4C ). Since C-Raf expression is reduced in many B-Raf mutant human melanoma cell lines, we sought to determine the effect of increased C-Raf levels on MAPK pathway activation and proliferation in such cells. Consistent with our prior findings regarding the properties of C-Raf in B-Raf V600E melanoma cells, we found that multiple melanoma cell lines would not support the stable ectopic expression of C-Raf. Therefore, the melanoma cell line WM793 was examined immediately following transfection with C-Raf, demonstrating that increased C-Raf levels can directly inhibit both the MAPK pathway ( Figure 4D ) and cellular Intriguingly, B-Raf V600E -C-Raf association was increased upon Hras G12V coexpression ( Figure 2B ). Hence, we hypothesized that oncogenic Ras could inhibit B-Raf V600E -mediated MAPK signaling by activating C-Raf and promoting B-Raf V600E -C-Raf interaction. Accordingly, Hras G12V was expressed in NIH 3T3
fibroblasts either alone or together with B-Raf V600E . Expression of Hras G12V resulted in elevated levels of pS338-CRaf, confirming increased C-Raf activation by Hras G12V ( Figure 5A ). In addition, B-Raf-C-Raf complexes and pERK levels were more abundant in cells expressing Hras G12V ( Figure 5A ). Thus, oncogenic
Ras induces MAPK signaling in fibroblasts through C-Raf activation and induction of B-Raf-C-Raf complexes. In contrast, Hras G12V -mediated induction of B-Raf-C-Raf complexes in NIH 3T3 fibroblasts expressing B-Raf V600E correlated with diminished MAPK pathway activation ( Figure 5B ). Moreover, increased proliferation conferred by either B-Raf V600E or Hras G12V was negated by concomitant expression of both oncogenes in NIH 3T3 cells ( Figure 5C ). To ascertain that complex formation is not due to overexpression of oncogenic B-Raf, similar experiments were performed in WM793 melanoma cells that express endogenous B-Raf -C-Raf complexes (Figures 6A and 6B) . Surprisingly, low concentrations of Sorafenib increased rather than inhibited ERK phosphorylation ( Figures  6A and 6B ). To exclude overexpression artifacts as a possible explanation for this observation, the response to Sorafenib was examined in WM164, A375P, and SKMel2 melanoma cells and mouse embryonic fibroblasts expressing endogenous B-Raf V619E . We found similar patterns of B-Raf V600E -C-Raf complex stabilization and pERK inhibition at high doses of Sorafenib in all examined cell lines. (Figure S6 ). However, increased pERK levels at low doses of Sorafenib were only observed in B-Raf V600E mutant cells (WM164, A375P, and MEFs), but not in SKMel2 cells, which carry an N-Ras mutation ( Figure S6 ). To determine whether stabilization of B-Raf V600E -C-Raf complexes leads to inhibition of MAPK activation, the sensitivity of D3-BRaf V600E to Sorafenib was assessed. Sorafenib increased association of C-Raf with D3-B-Raf V600E in a dose-dependent manner; however, the amount of complexes was lower compared to Sorafenib-induced full-length B-Raf V600E -C-Raf complexes ( Figure 6C ). Moreover, cells expressing D3-B-Raf V600E were more resistant to high concentrations of Sorafenib than FL-BRaf V600E -expressing cells. While treatment with 3 mM Sorafenib significantly reduced pERK levels compared to the 0.3 mM dose when FL-B-Raf V600E was expressed, no pronounced decrease in pERK levels was observed in D3-B-Raf V600E -expressing cells at these concentrations ( Figure 6D ). Thus, promoting suppression of B-Raf V600E through stabilization of B-Raf V600E -C-Raf complexes may be an additional mode of action of Sorafenib. We reasoned that the increased pERK levels noted at low doses of Sorafenib may be due to induction of active protein complexes containing only B-Raf B-Raf V600E alone ( Figure 6E ). These findings suggest that Sorafenib-induced stabilization of B-Raf V600E -C-Raf complexes with low kinase activity contributes to the therapeutic activity of this small molecule inhibitor.
DISCUSSION
Activating mutations in Ras and B-Raf are commonly found in cancer and lead to deregulation of the MAPK pathway. Investigating this aberrant regulation of the MAPK signaling cascade in cancer could identify useful therapeutic targets to combat the disease. In this study, we report a suppressive function of the proto-oncogene C-Raf on oncogenic B-Raf ERK. This finding was surprising because B-Raf-C-Raf complexes were reported to possess higher kinase activity toward MEK than B-Raf-B-Raf and C-Raf-CRaf complexes (Rushworth et al., 2006) . A potential explanation could be the restriction of B-Raf V600E protein dynamics and therefore catalytic activity by its association with C-Raf. As wild-type A-Raf or B-Raf bind to B-Raf V600E but don't inhibit the activity of B-Raf
V600E
, such complexes are likely distinct in their quaternary structure or contain different additional binding partners compared to the B-Raf V600E -C-Raf complexes. Whether C-Raf has a similar inhibitory influence on wild-type B-Raf-mediated MAPK activation in cells is incompletely understood. Indeed, genetic ablation of C-Raf increases B-Raf activity and phosphorylation of MEK in fibroblasts (Mikula et al., 2001) , indicating that C-Raf may negatively modulate MAPK signaling under certain conditions. These data suggest that the composition and abundance of Raf complexes play pivotal roles in regulating the extent of MAPK pathway activation under normal and pathological conditions. The relative cellular amounts of B-Raf and C-Raf may affect the formation of Raf complexes and thus the susceptibility of certain cell types to transformation by different oncogenic B-Raf mutants. This is supported by the fact that the occurrence of the V600E mutation is relatively rare in cancers that more commonly carry impaired-activity B-Raf mutations, such as the lung (see COSMIC database for B-Raf mutation data in cancer, http://www.sanger.ac.uk/genetics/CGP/cosmic/). C-Raf has been previously demonstrated to antagonize other serine/threonine kinases through physical interaction. Binding of C-Raf to the proapoptotic kinases MST2 (O'Neill et al., 2004) and ASK1 (Chen et al., 2001 ) prevents their activation and protects cells from apoptosis. Moreover, C-Raf inhibits Rok-a, thereby regulating cell motility and death (Piazzolla et al., 2005) . Similar to MST2 (O'Neill et al., 2004) , suppression of B-Raf V600E is specific to C-Raf, as wild-type B-Raf could not inhibit B-Raf
. C-Raf exerts its inhibitory functions on MST2, ASK1, and Rok-a independent of its kinase activity and MEK/ ERK signaling. To address whether C-Raf kinase activity is required for suppression of B-Raf V600E , we determined MAPK activation by B-Raf V600E in the presence of two C-Raf mutants with severely impaired catalytic activity. Interestingly, suppression of B-Raf V600E by wild-type and mutant C-Raf correlated with the efficiency of complex formation rather than C-Raf activity. Moreover, we did not observe changes in Ser/Thr phosphorylation of immunoprecipitated B-Raf V600E when coexpressed with C-Raf (data not shown), and thus kinase activity appears to be dispensable for the antagonistic effect of C-Raf.
Reduced binding of C-Raf K375M to B-Raf has been noted before (Rushworth et al., 2006) and could be due to a conformational change induced by the K375M mutation, thereby impairing interaction. In contrast, the association of C-Raf with MST2, ASK1, and ROK-a is unaffected by the K375M mutation. Whether the catalytic lysine at position 375 of C-Raf is crucial for complex formation with B-Raf remains to be determined. Therefore, these findings suggest that the interaction of C-Raf with B-Raf V600E directly lowers the kinase activity of B-Raf V600E . We found that the C-Raf expression levels are reduced relative to B-Raf levels in human melanoma cell lines expressing B-Raf
. Interestingly, cells derived from early tumor stages (radial and vertical growth phase) contained decreased C-Raf protein levels, while metastasis-derived cell lines harbored increased B-Raf protein levels and therefore a reduced C-Raf: B-Raf ratio. Previously, C-Raf mRNA levels were found to be lower in B-Raf V600E melanoma cells compared to cells expressing wild-type B-Raf, suggesting transcriptional regulation as a potential mechanism of C-Raf reduction (Pavey et al., 2004) . We have confirmed that the B-Raf mRNA levels are higher than that of C-Raf in B-Raf V600E -expressing melanoma cells (data not shown), although translational and posttranslational processes may also participate in our findings. Nonetheless, the reduced ratio of C-Raf:B-Raf protein levels in B-Raf V600E -expressing melanoma cells relative to melanocytes is likely to alleviate suppression of B-Raf
. This hypothesis is substantiated by our observation that C-Raf and B-Raf molecules are present at near-equimolar amounts in these cells. Therefore, changes in the stoichiometry could impact the formation of Raf complexes. Further evidence for a suppressive function of C-Raf in B-Raf V600E -expressing human melanoma cell lines comes from the observation that stable cell lines expressing ectopic C-Raf or ectopic Ras could not be isolated. Invariably, expression of these cDNAs was rapidly downregulated or lost, indicating that B-Raf V600E -C-Raf complex formation by forced expression of high C-Raf or Ras levels is not tolerated by these cells. Together, these findings support the premise that B-Raf V600E -expressing cells circumvent C-Raf's antagonistic function by reducing C-Raf levels relative to B-Raf, thereby creating an intracellular environment that facilitates hyperactivation of the MAPK pathway and cellular transformation.
B-Raf V600E and oncogenic Ras mutations are mutually exclusive in human cancer, which has previously been attributed to redundant MAPK pathway activation by the two oncogenes. We demonstrate here that oncogenic Ras activates C-Raf, leading to an interaction with B-Raf V600E and inhibition of its cat- (Thomas et al., 2007) , consistent with the increased association of B-Raf
G466V
with C-Raf and ERK activation upon expression of Hras G12V , as observed in this study. C-Raf activation by impaired-activity mutant B-Raf occurs independently of Ras (Garnett et al., 2005) ; however, we propose that C-Raf activation is further increased by oncogenic Ras, thereby enhancing MAPK signaling. Thus, co-occurrence of oncogenic Ras and impairedactivity mutant B-Raf cooperates to deregulate the MAPK pathway, resulting in signal intensities that may enhance oncogenesis of certain tumor types. Sorafenib inhibits C-Raf more potently than B-Raf and B-Raf V600E (Wilhelm et al., 2004) . While high doses of Sorafenib inhibited MAPK signaling, lower doses partially rescued C-Rafinduced suppression of B-Raf V600E signaling (Figure 6 ). Importantly, cells expressing either D3-B-Raf V600E or no ectopic C-Raf were more resistant to Sorafenib at high doses. Therefore, the Sorafenib-mediated interaction of C-Raf with B-Raf V600E and the consequential decrease in catalytic activity may be an additional mode of action of Sorafenib. Increased MAPK pathway activation at low concentrations may be due to Sorafenibinduced association of B-Raf V600E with wild-type or mutant B-Raf, which could augment B-Raf V600E activity. Indeed, (Eisen et al., 2006) . Tumors carrying impaired-activity mutant B-Raf, however, were not evaluated and may be more responsive to pan-Raf inhibitors such as Sorafenib. Therefore, determining the B-Raf mutational status could be imperative for the right choice of treatment. Our finding that proto-oncogenic C-Raf exhibits suppressive activity toward B-Raf V600E should encourage investigations into the development of inhibitors that efficiently and selectively stabilize B-Raf V600E -C-Raf complexes for the treatment of cancers harboring this mutation.
EXPERIMENTAL PROCEDURES Plasmids B-Raf was PCR amplified from mouse cDNA, a Flag tag, or an HA tag introduced at the C terminus and cloned into pBabe-puro or pWZL-hygro, respectively. Mutant variants were generated using a site-directed mutagenesis kit (Stratagene).
Cell Lines and Transfections
HEK293T and NIH 3T3 cells were obtained from ATCC and cultured in DMEM (Invitrogen) containing 10% fetal calf serum (Hyclone), 100 U/mL penicillin, and 100 mg/mL streptomycin (both Invitrogen). NHEMs were obtained from PromoCell and cultured in melanocyte growth medium (PromoCell). Melanoma cell lines were a kind gift from M. Herlyn (Wistar Institute, Philadelphia) and cultured in DMEM containing 10% fetal calf serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. Melan-a cells were a kind gift from D. Bennett (St. George's University, London) and were cultured in RPMI (Invitrogen) containing 10% fetal calf serum, 100 U/mL penicillin, and 100 mg/mL streptomycin and 200 mM TPA (Sigma). HEK293T cells were plated 24 hr before transient transfection using Fugene 6 (Roche) or Lipofectamine 2000 (Invitrogen). Transfected HEK293T cells were used for experiments 48 hr after transfection. NIH 3T3 fibroblasts were infected with retroviruses produced in the Phoenix packaging cell line in the presence of 8 mg/ml polybrene and were selected with puromycin or hygromycin 48 hr after infection. For knockdown experiments, we used the pSuper-retro-puro vector containing short hairpins targeting human C-Raf and a scrambled control. shRNA sequences were published previously (Hingorani et al., 2003) .
Immunoprecipitation
Cells were washed twice with PBS and lysed in ice-cold RIPA lysis buffer. Of total lysate, 400 mg was precleared for 20 min and then immunoprecipitated with 20 ml of ANTI-FLAG M2 agarose beads (Sigma) or ANTI-HA agarose beads (Sigma) for 2 hr at 4 C. Beads were washed four times with RIPA lysis buffer and subjected to SDS-PAGE. For kinase assays, HA-B-Raf
V600E
, HA-B-Raf, or myc-C-Raf was coexpressed with Flag-B-Raf
. HA-tagged and myc-tagged components of the complexes were immunoprecipitated for 6 hr from 600 mg of total lysate using ANTI-HA agarose beads or ANTImyc agarose beads, respectively. Complexes were eluted twice using 200 mg/ml HA-or myc-peptide in TBS for 30 min at 4 C, diluted with RIPA lysis buffer, and subjected to a Flag-IP overnight to isolate specific HA-tagged/ Flag-tagged or myc-tagged/Flag-tagged protein complexes. Beads were washed four times with RIPA lysis buffer and used in a MAPK sandwich kinase assay with 32 P-g-ATP, using MBP as final substrate (Millipore) according to the manufacturer's recommendations. Kinase reactions were analyzed by SDS-PAGE and autoradiography to detect 32 P-g-labeled MBP. The beads from the Flag-IP were used to detect the amount of immunoprecipitated Flag-BRaf V600E by western blotting, and the phospho-MBP signal was normalized to immunoprecipitated Flag-B-Raf
.
Western Blotting
Protein lysates and immunoprecipitates were separated on precast NuPAGE Novex 4%-12% Bis-Tris gradient gels (Invitrogen), transferred onto a PVDF membrane (Millipore) and incubated overnight with one of the following primary antibodies: HA, Flag, phospho-ERK1/2, ERK1/2, phospho-MEK1/2, or MEK1/2 (all Cell Signaling); C-Raf, B-Raf, or actin (all Santa Cruz Biotechnologies); panRas (Calbiochem); or phospho-S338-C-Raf, myc, A-Raf, DUSP4, DUSP6, or Sprouty 2 (all Abcam). Membranes were incubated with secondary HRP antibodies (Jackson ImmunoResearch) for 1 hr followed by signal detection with enhanced chemiluminescence and X-ray film (both Amersham). Alternatively, membranes were incubated with Alexa Fluor secondary antibodies (Invitrogen) for 1 hr and scanned using Li-Cor Odyssey. Signal was quantified using Odyssey software.
Proliferation and Soft Agar Assays Cells (2.0-2.5 3 10 4 ) were plated in triplicates in 12-well plates and counted every day for 4 days for proliferation of melan-a and NIH 3T3 cells or counted every other day for 7 days for proliferation of WM793 cells. Alternatively, cells were incubated with BrdU for 6 hr and proliferating cells detected using an anti-BrdU antibody (B&D) following the manufacturer's instructions. For soft agar assays, 5 3 10 4 cells were resuspended in 0.4% agar and plated over 0.8% agar. Colonies were stained with Giemsa after 3 weeks.
RNA Isolation, cDNA Synthesis, and PCR Analysis RNA was isolated from mouse tissues with TRIzol reagent (Invitrogen). RNA (2-4 mg) was used for cDNA synthesis using Ready-To-Go You-Prime FirstStrand Beads (Amersham Biosciences) following the manufacturer's recommendations. For PCR analysis of exon 3, primers binding to exons 2 and 4 were designed.
Statistical Analysis
All experiments were repeated at least three times and done in triplicate.
Western blot experiments that showed modest changes were repeated five times and quantified each time. Data were accepted as reproducible when similar results with consistent changes were observed in all five experiments. Statistical analysis was performed using Student's t test, p < 0.05 was accepted as significant. Data are shown as mean, and error bars represent the standard deviation.
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